Vitek. Mercedes M; Zvonar Pobirk. Alenka A; Roškar. Robert R; Matjaž. Mirjam Gosenca MG
Researchers created a new injectable gel that turns into a liquid crystal under the skin and slowly releases the peptide thymosin‑alpha‑1 for up to two weeks in lab tests. This could cut the number of injections needed, but the method still needs more development before everyday users can apply it.
Scientists gave mice a probiotic (Bifidobacterium longum) that was engineered to make the immune‑boosting peptide thymosin‑alpha‑1, and the mice ate it. Over two weeks the mice showed more active T‑cells and higher levels of immune‑activating signals, and after three months their thymus and lymph nodes grew larger. This shows oral delivery of thymosin‑alpha‑1 can work in animals, but it’s still early‑stage and not ready for people to try.
Liao. Jing J; Li. Yu-Pin YP; Huang. Jian-Ming JM; Li. Ge G
The study shows that the immune‑boosting peptide thymosin‑alpha‑1 can lower the activity of an enzyme (IDO) that helps leukemia cells hide from the immune system, and it can block the boost that interferon‑γ gives to this enzyme. This suggests thymosin‑alpha‑1 might help the body fight certain cancers, but the work was done in cell lines, not people.
Yu. Rong R; Sun. Yu Y; Cai. Qing Q; Li. Yongheng Y; Zhu. Guangying G
In a mouse study, giving thymosin‑alpha‑1 together with radiation lowered death rates and reduced lung damage compared to radiation alone, showing it can protect the lungs from radiation‑induced injury.
Scientists found that adding the peptide thymosin‑alpha‑1 to a virus that attacks cancer cells can change immune cells in the tumor from a “bad” type that helps the tumor grow to a “good” type that fights the tumor, making the treatment work better.
Renga. Giorgia G; Bellet. Marina M MM; Pariano. Marilena M; Gargaro. Marco M; Stincardini. Claudia C...
Researchers found that the natural peptide thymosin‑alpha‑1 can protect mice from gut inflammation caused by cancer drugs that block the CTLA‑4 checkpoint. It does this by turning on a tolerance pathway (IDO1) in the intestine and reshaping immune cell balances, without affecting the tumor itself.
In a lab study, adding thymosin‑alpha‑1 to blood cells from stomach‑cancer patients raised the number of regulatory T cells (which can dampen immune attacks) and increased inflammatory signals like IL‑1β, TNF‑α, and IL‑6. The work was done in vitro at a concentration of 50 µg/mL and shows the peptide can shift immune balance, but it doesn’t prove a health benefit for healthy people.
The study shows that the peptide thymosin‑alpha‑1 can stick to the enzyme ACE and lower the amount of ACE2 on lung cells, which are the doorways the coronavirus uses to get inside. It also slightly blocks ACE activity, but it doesn't change other related hormones. This suggests thymosin‑alpha‑1 might help reduce the chance of COVID‑19 infection, though the work was done in lab cells, not people.
A study showed that the peptide thymosin‑alpha‑1 can calm down the overactive immune response seen in COVID‑19 patients by lowering cytokine production and slowing certain T‑cell activity when tested on blood cells outside the body. This suggests it might help keep the immune system balanced during severe infections.
A review of 12 small studies suggests that giving the peptide thymosin‑alpha‑1 to people with severe infections (sepsis) might lower the chance of dying, but the research quality is low and more big, well‑run trials are needed before it can be recommended for everyday use.
Wang. Xinying X; Li. Weiqin W; Niu. Chenglin C; Pan. Liya L; Li. Ning N; Li. Jieshou J
In a small study of 24 people with severe pancreas inflammation, giving the peptide thymosin‑alpha‑1 (3.2 mg twice daily for a week) helped their immune cells recover faster, cut infection rates, and shortened time in the ICU. The results are promising for immune support in very sick patients, but the data are limited to a specific disease and a short treatment course.
Wan. Jian J; Shan. Yi Y; Shan. Hongwei H; Li. Guomin G; Wang. Tao T; Guan. Jun J; Liu. Xuefeng X; Ch...
In a mouse model of severe infection (sepsis), giving the peptide thymosin‑alpha‑1 helped more mice survive for 72 hours. It did this by lowering the number of suppressive regulatory T cells, making more of them die, and balancing inflammatory signals in the blood.
Thymosin alpha‑1 is a short protein that can boost immune cells, help the body make more antibodies, and protect certain cells from steroid damage. This paper mainly talks about new ways to make the peptide using bacteria or other cells, which could eventually lower the price, but it doesn’t give new dosing or usage tips for everyday users.
Aynekulu Mersha. Daniël G DG; Fromme. Sarah E SE; van Boven. Frank F; Arteaga-Henríquez. G...
A tiny open‑label study gave five people with a rare immune disorder (CVID) and depression daily thymosin‑alpha‑1 injections for a week, then twice a week for seven weeks. Their depression scores dropped about half, and their immune cells (naïve T‑cells) improved. When the drug stopped, the two worst patients got depressed again. The results hint that thymosin‑alpha‑1 might lift mood by fixing immune problems, but the study is tiny and only in a special patient group.
Thymosin alpha‑1 is a peptide that can boost the immune system and has been tested as an add‑on to standard hepatitis C drugs. Some early studies hinted it might help people who don’t respond well to the usual treatment, but larger, well‑designed trials haven’t confirmed a clear benefit yet.
Chiriva-Internati. M M; Wachtel. M S MS; Frezza. E E EE
A small study gave sepsis patients a combo of two drugs—ulinastatin and thymosin‑alpha‑1—and saw better survival (78% vs 60%) and faster recovery of immune and blood‑clotting markers, but the research was done on very sick hospital patients, not healthy people.
Liu. Fangjie F; Qiu. Bo B; Xi. Yu Y; Luo. Yifeng Y; Luo. Qiaoting Q; Wu. Yingjia Y; Chen. Naibin N;...
In a trial with lung‑cancer patients getting chemo‑radiation, adding the peptide thymosin‑alpha‑1 each week reduced serious lung inflammation and helped keep white‑blood‑cell counts higher compared with similar patients who didn’t get the peptide.
Zhou. Liang L; Lai. Zong-Teng ZT; Lu. Min-Kan MK; Gong. Xing-Guo XG; Xie. Yi Y
Scientists figured out a way to make the immune‑boosting peptide thymosin‑alpha‑1 in bacteria and then cut it out into its active form, showing it still works in lab tests. The method could let people produce the peptide themselves, but it needs a molecular‑biology setup and doesn’t give dosing or safety info for human use.
Grandini. E E; Cannoletta. F F; Scuteri. A A; Fortini. C C; Loggi. E E; Cursaro. C C; Riili. A A; Di...
Adding thymosin‑alpha‑1 to the usual hepatitis C drugs didn’t change the main T‑cell numbers, but it did cause natural‑killer (NK) cells to rise sooner. The study was tiny (24 people) and only looked at HCV patients who hadn’t responded to other treatments, so it’s not a clear guide for general health use.
Volk. David E DE; Tuthill. Cynthia W CW; Elizondo-Riojas. Miguel-Angel MA; Gorenstein. David G DG
Thymosin α1 is a tiny immune‑boosting peptide that doesn’t have a fixed shape in water, but it can fold into a helix when it meets certain chemicals or cell‑membrane‑like environments, which may affect how it works in the body.